SCYNEXIS INC
SCYXNext catalyst
Phase 1 — SCY-247
Get an email about SCYX's next catalysts
Track SCYNEXIS (SCYX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 1 past
Phase 1 — SCY-247
SCYNEXIS has dosed the first participants in a Phase 1 single and multiple ascending dose trial of intravenous SCY-247, with results expected in 2026.
SourceMarket Overview
Stock performance and key metrics
SCY-078
Mycoses
Ibrexafungerp
Candida Vulvovaginitis
Fluconazole Tablet
Recurrent Vulvovaginal Candidiasis
SCY-635
Hepatitis C Infection
Copegus
Hepatitis C Infection
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SCY-078 | Phase 3 | Mycoses | - | - |
Ibrexafungerp | Phase 3 | Candida Vulvovaginitis | - | - |
Fluconazole Tablet | Phase 3 | Recurrent Vulvovaginal Candidiasis | - | - |
SCY-635 | Phase 2 | Hepatitis C Infection | - | - |
Copegus | Phase 2 | Hepatitis C Infection | - | - |
Frequently asked questions
What is in SCYNEXIS INC's drug pipeline?→
CatalystAlert tracks 5 drug candidates in SCYNEXIS INC's (SCYX) pipeline across Phase 3, Phase 2. Its lead program is Fluconazole Tablet (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is SCYNEXIS INC's next FDA catalyst?→
SCYNEXIS INC's (SCYX) next tracked catalyst is a Phase 1 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SCYX biotech catalysts?→
Add SCYX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow SCYNEXIS INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.